CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease

Mitsuhiro Akiyama; Hidekata Yasuoka; Keiko Yoshimoto; Tsutomu Takeuchi

doi:10.1136/annrheumdis-2017-212110

CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease

Mitsuhiro Akiyama, Hidekata Yasuoka, Keiko Yoshimoto, Tsutomu Takeuchi

研究成果: Letter › 査読

本文言語	English
ページ（範囲）	1386-1387
ページ数	2
ジャーナル	Annals of the rheumatic diseases
巻	77
号	9
DOI	https://doi.org/10.1136/annrheumdis-2017-212110
出版ステータス	Published - 2018 9月 1

ASJC Scopus subject areas

免疫アレルギー学
リウマチ学
免疫学
生化学、遺伝学、分子生物学（全般）

文献へのアクセス

10.1136/annrheumdis-2017-212110

他のファイルとリンク

引用スタイル

@article{48fb0df8fe1b4f329df094de211141be,

title = "CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease",

keywords = "autoimmunity, chemokines, cytokines, disease activity",

author = "Mitsuhiro Akiyama and Hidekata Yasuoka and Keiko Yoshimoto and Tsutomu Takeuchi",

note = "Funding Information: Competing interests MA has received consultancies, speaking fees and honoraria from Asahi Kasei Co, Cure Grades Co, and Eisai Co., and a research grant from Mitsubishi Tanabe Pharma Co. TT has received consulting fees, speaking fees and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than $10 000 each) and Chugai Pharmaceutical, Bristol-Myers K.K, Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K, Pfizer Japan, Asahi Kasei Pharma, Funding Information: Funding This study was supported by an institutional research grant from Keio University and by Mitsubishi Tanabe Pharma Company, Japan.",

year = "2018",

month = sep,

day = "1",

doi = "10.1136/annrheumdis-2017-212110",

language = "English",

volume = "77",

pages = "1386--1387",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "9",

}

TY - JOUR

T1 - CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease

AU - Akiyama, Mitsuhiro

AU - Yasuoka, Hidekata

AU - Yoshimoto, Keiko

AU - Takeuchi, Tsutomu

N1 - Funding Information: Competing interests MA has received consultancies, speaking fees and honoraria from Asahi Kasei Co, Cure Grades Co, and Eisai Co., and a research grant from Mitsubishi Tanabe Pharma Co. TT has received consulting fees, speaking fees and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than $10 000 each) and Chugai Pharmaceutical, Bristol-Myers K.K, Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K, Pfizer Japan, Asahi Kasei Pharma, Funding Information: Funding This study was supported by an institutional research grant from Keio University and by Mitsubishi Tanabe Pharma Company, Japan.

PY - 2018/9/1

Y1 - 2018/9/1

KW - autoimmunity

KW - chemokines

KW - cytokines

KW - disease activity

UR - http://www.scopus.com/inward/record.url?scp=85045621309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045621309&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2017-212110

DO - 10.1136/annrheumdis-2017-212110

M3 - Letter

C2 - 29030359

AN - SCOPUS:85045621309

SN - 0003-4967

VL - 77

SP - 1386

EP - 1387

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 9

ER -